Helus Pharma™ Announces US$50 Million Underwritten Offering (opens original article in a new tab)

Helus Pharma has priced a US$50 million underwritten offering of common shares, with proceeds intended for clinical trials and corporate purposes.

• Helus Pharma announces a US$50 million underwritten offering of 10,309,280 common shares at US$4.85 each.
• The offering is led by Cantor and Barclays as joint bookrunning managers, with Bloom Burton Securities and Lucid Capital Markets as lead managers.
• Proceeds will fund Phase 3 trials for HLP003, Phase 2 trials for HLP004, and general corporate purposes.